LabCorp Extends Proposed Orchid Cellmark Buy Again | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today announced it is further extending its cash tender offer for Orchid Cellmark as it continues to provide answers to questions about the deal to the US Federal Trade Commission.

The $85.4 million proposed deal, announced in April, has been extended to 5 p.m. EDT, Nov. 14. It was previously extended to Nov. 4, and now has been extended eight times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.